SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs 100th Electron launch drew excitement, with traders celebrating a flawless milestone flight. The discussion also weighs strong revenue and backlog growth against Neutrons delay into 2027, with bulls focused on demand and bears concerned about execution, losses and valuation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs steep decline amid a broader crypto selloff is dominating discussion, with traders focused on the loss of a key psychological support level. The community is split between dip-buyers who see a potential bottom and bearish traders warning of further downside; some also blame Bitcoin weakness and concerns about Ripple and its executives.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

The FAAs nationwide ground stop after an air-traffic-control communications outage is driving attention to Delta and other airlines, with traders weighing ongoing delays and cancellations against the restriction being lifted. Speculation about a cyberattack or deliberate cause is circulating, but the outages root cause remains under investigation.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs quarterly results are driving discussion: traders point to improving margins and the newly authorized share repurchase, but the stocks decline has some focused on rising operating costs, debt, and sensitivity to interest rates and housing demand. Views are split between investors who see progress in integrating acquisitions and those who see few near-term catalysts.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra shares fell sharply after the CHMP reaffirmed its negative opinion on MIPLYFFA (arimoclomol) for Niemann-Pick disease type C in Europe, with a final European Commission decision still pending. Traders are split between viewing the setback as largely expected and an overreaction, emphasizing U.S. sales and cash, while others criticize management and question the companys path in Europe.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

A nationwide FAA ground stop stemming from an air-traffic-control communications outage disrupted flights and weighed on airline shares. Traders largely debate whether the impact is temporary as flights resume, while cyberattack and AI explanations remain speculation without confirmation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Recent court filings extending deadlines in Aurinias Lupkynis patent litigation are driving discussion, with traders parsing whether the delays signal progress toward a settlement or continued disputes with generic-drug makers. Many also criticize CEO Kevin Tangs limited communication, while any near-term deal remains speculation.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

Rising concern about AI-enabled cyber threats is driving attention to SentinelOne, with traders also speculatingwithout confirmationthat the FAAs nationwide flight ground stop had a cybersecurity angle. Bulls point to the companys valuation discount and potential demand or takeover interest, while skeptics question its execution and volatile share performance.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,140,678.86417527 in circulation. The last known price of Hedera is 0.06118377 USD and is down -3.83 over the last 24 hours. It is currently trading on 468 active market(s) with $73,346,897.90 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention amid persistent price weakness, with traders debating whether token dilution, weak fee demand, and limited adoption are weighing on the token. Some holders are buying the dip, while skeptics call the rallies pump-and-dumps and question whether enterprise partnerships translate into demand for HBAR.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below key technical support levels dominate the discussion, with traders debating whether the decline signals a deeper bear market or an oversold dip that could rebound. Some also point to macroeconomic pressure, including a stronger dollar and higher yields, while others argue that dip buyers are absorbing the selling.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI, Cancer Vaccines, and Next-Gen Medicine 

Could cancer vaccines and AI drive the next wave of healthcare innovation?

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Biotech ETF (CANC) Hits New 52-Week High

CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%

Equity

H.C. Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy achieved its primary endpoint in a Phase 3 trial.

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

Why Did GLUE Stock Surge Over 50% In Premarket Today?

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Temas Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance

Tema ETFs (Tema), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (CANC) has surpassed $100m in assets under management (AUM) two...

Be Thankful to These ETFs This Year 

Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



Tema ETF Trust - Tema Oncology ETF

Neutral Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised its price target to $165 from $94, citing positive Phase 3 trial results.</li><li>Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating.</li><li>The firm highlighted expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.</li></ul>Celcuity Inc. (CELC) could become an acquisition target in the oncology space, according to analysts, after the company reported positive results in the Phase 3 trial of its breast cancer therapy.According to TheFly, analysts at HC Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy, gedatolisib, achieved its primary endpoint in a Phase 3 trial.<a href="https://stocktwits.com/symbol/CELC">Celcuity shares</a> were up more than 15% in Monday’s pre-market trade, extending the gains from Friday. If CELC stock ends Monday’s regular trading session with these gains, it would be the stock’s best single-day gain in more than six months.Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Why Are Analysts Optimistic?</h2>Analysts at H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised their price target to $165 from $94, citing positive Phase 3 trial results. The firm said gedatolisib has the potential to be a “game-changing” treatment for HR+/HER2- advanced breast cancer and could position Celcuity as an acquisition target.Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating. The firm said the data suggest the drug could expand its use in second-line ER+/HER2- advanced breast cancer, demonstrating benefit regardless of PI3K mutation status.It also pointed to expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.Stifel analyst Stephen Willey raised the firm’s price target on Celcuity to $150 from $125 and maintained a ‘Buy’ rating. Willey said the “statistically significant and clinically meaningful” improvement in the Phase 3 trial was largely expected, but noted that its selection as a late-breaking oral presentation at the ASCO Annual Meeting on June 2 was the bigger surprise.<h2 class="st-heading-2">Celcuity’s Latest Announcement</h2>Celcuity reported positive Phase 3 results for gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer after prior CDK4/6 and aromatase inhibitor treatment.The company stated that the gedatolisib triplet regimen met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared with alpelisib plus fulvestrant.The gedatolisib doublet also delivered a statistically significant PFS benefit compared with the control arm, despite being a secondary endpoint; both regimens demonstrated manageable safety profiles with no new safety concerns.HR+/HER2- breast cancer is the most common form of the disease, representing about 70% of all cases. Within this group, roughly 40% of patients carry PIK3CA mutations.<a href="https://stocktwits.com/symbol/CELC">CELC stock</a> is up 26% year-to-date and 1,063% over the past 12 months. The Tema Oncology ETF (CANC) is up 50% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 58%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gamestop-ryan-cohen-ebay-build-larger-business-gme-ebay-stock/cZQMpRjReJc">GameStop's Ryan Cohen Says He Plans On Bringing An Entrepreneurial Mindset To eBay And Building Something 'Much Larger'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tema Oncology ETF

Celcuity Inc

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

CANC News